Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 49, 2012, Pages 20071-20076

  Bénéteau, Marie ^a,b   Zunino, Barbara ^a,b,c   Jacquin, Marie A ^a,b   Meynet, Ophélie ^a,b   Chiche, Johanna ^a,b   Pradelli, Ludivine A ^a,b   Marchetti, Sandrine ^a,b   Cornille, Aurore ^a,b   Carles, Michel ^a,c   Ricci, Jean Ehrland ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Apoptosis; DAMP; Lymphoma

Indexed keywords

CALRETICULIN; DEOXYGLUCOSE; ETOPOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CELL MEMBRANE; CONTROLLED STUDY; CYTOTOXICITY; EX VIVO STUDY; FEMALE; GLYCOLYSIS; IMMUNOGENICITY; LIFESPAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BLOTTING, WESTERN; CALRETICULIN; CELL DEATH; CELL LINE, TUMOR; DEOXYGLUCOSE; DRUG THERAPY, COMBINATION; ETOPOSIDE; GLYCOLYSIS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RNA INTERFERENCE; T-LYMPHOCYTES;

ANIMALIA; MUS;

EID: 84870589378     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1206360109     Document Type: Article

References (30)

1. Vander Heiden MG (2011) Targeting cancer metabolism: A therapeutic window opens. Nat Rev Drug Discov 10(9):671-684.
2. Muñoz-Pinedo C, El Mjiyad N, Ricci JE (2012) Cancer metabolism: Current perspectives and future directions. Cell Death Dis 3:e248.
3. El Mjiyad N, Caro-Maldonado A, Ramírez-Peinado S, Muñoz-Pinedo C (2011) Sugarfree approaches to cancer cell killing. Oncogene 30(3):253-264.
4. KurtogluM, et al. (2007) Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther 6(11):3049-3058. (Pubitemid 350206783)
5. Ralser M, et al. (2008) A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growth. Proc Natl Acad Sci USA 105(46):17807-17811.
6. Dwarakanath B, Jain V (2009) Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. Future Oncol 5(5):581-585.
7. Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat Rev Immunol 6(10):715-727. (Pubitemid 44453458)
8. Balachandran VP, et al. (2011) Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 17(9):1094-1100.
9. Obeid M, et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54-61. (Pubitemid 46067386)
10. Zitvogel L, Kepp O, Kroemer G (2010) Decoding cell death signals in inflammation and immunity. Cell 140(6):798-804.
11. Adams JM, et al. (1985) The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318(6046):533-538. (Pubitemid 16173038)
12. Lindemann RK, et al. (2007) Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 104(19):8071-8076. (Pubitemid 47185877)
13. Mason KD, et al. (2008) In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci USA 105(46):17961-17966.
14. Meynet O, et al. (2012) Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis. Leukemia 26(5):1145-1147.
15. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440-446.
16. Kelly PN, Puthalakath H, Adams JM, Strasser A (2007) Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma. Blood 109(11):4907-4913. (Pubitemid 46827788)
17. Tesniere A, et al. (2010) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29(4):482-491.
18. Panaretakis T, et al. (2009) Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28(5):578-590.
19. Saito S, et al. (2009) Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. Cancer Res 69(10):4225-4234.
20. Panaretakis T, et al. (2008) The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 15(9):1499-1509.
21. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
22. Garg AD, et al. (2010) Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation. Biochim Biophys Acta 1805(1):53-71.
23. Stein M, et al. (2010) Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 70(13):1388-1394.
24. Watanabe K, Bois FY, Zeise L (1992) Interspecies extrapolation: A reexamination of acute toxicity data. Risk Anal 12(2):301-310.
25. Wang R, et al. (2011) The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35(6):871-882.
26. Dréau D, et al. (2000) Immune alterations in three mouse strains following 2-deoxy-Dglucose administration. Physiol Behav 70(5):513-520.
27. Dréau D, Morton DS, Foster M, Fowler N, Sonnenfeld G (1998) Effects of 2-deoxy-Dglucose administration on immune parameters in mice. Immunopharmacology 39(3): 201-213. (Pubitemid 28432064)
28. Merchan JR, et al. (2010) Antiangiogenic activity of 2-deoxy-D-glucose. PLoS One 5(10):e13699.
29. Lavallard VJ, et al. (2009) Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells. Cancer Res 69(7):3013-3020.
30. Landázuri N, Le Doux JM (2006) Complexation with chondroitin sulfate C and Polybrene rapidly purifies retrovirus from inhibitors of transduction and substantially enhances gene transfer. Biotechnol Bioeng 93(1):146-158. (Pubitemid 43117067)